UNION, N.J. — September 10, 2025 — Leads & Copy — NanoNewron, a biotechnology company focused on treatments for central nervous system neurodegenerative diseases, has been awarded a $2.5 million NIH STTR Phase 2 grant. The funding will support the development of NN-840, an innovative TNF-alpha inhibitor program for Alzheimer’s disease and other neurodegenerative conditions, with an IND submission expected next year.
The company’s CEO, Dr. Marco Taglietti, stated the grant validates NanoNewron’s approach to Alzheimer’s, addressing the need for more effective treatments. Dr. Luciano D’Adamio, Chief Scientific Officer, added that the company’s TNF-alpha inhibitor antibodies combined with NewroBusTM technology have shown promising results in animal models. According to Deborah Perez Fernandez, executive director of the Office for Research (OfR) Technology Transfer unit of Rutgers University, Dr. D’Adamio’s innovations have the potential to make a positive impact for so many families around the world.
NanoNewron is developing humanized biologics that cross the blood-brain barrier (BBB) to treat CNS diseases, targeting neuroinflammatory and neurodegenerative conditions like Alzheimer’s. Its NewroBusTM technology enhances the delivery of biologic therapeutic agents to the CNS, increasing their bioavailability. The NN-840 program, utilizing proprietary TNF-alpha inhibitors and NewroBusTM, is advancing through preclinical evaluation.
Bahar Aksoy, NanoNewron Chief of Staff, bahar.aksoy@nanonewron.com +1 (908) 723-5006
Source: NanoNewron
